![]() ![]() “We’re now a $260 million laboratory business, as opposed to the tiny $30 million genetic testing business we were pre-pandemic,” said Brandon Perthuis, Fulgent’s chief commercial officer. ![]() ![]() And it’s a much larger company than before the pandemic hit. Now the company is transitioning to a diverse platform of clinical diagnostics and drug development business lines, using some of the cash left over from the Covid testing bonanza to fuel the shift. In its second-quarter earnings report released earlier this month, Covid testing accounted for less than $1 million in revenue for Fulgent, down from $128 million for the same quarter two years ago. Information on services and procedures provided to Original Medicare (fee-for-service) Part B (Medical Insurance) beneficiaries by Inform Diagnostics, Inc Number of HCPCS 85 Number of Medicare Beneficiaries 88121 Number of Services 362298 Total Submitted Charge Amount 81037226.13 Total Medicare Allowed Amount 23098970.26 Total Medicare Payment Amount 18842466.16 Total Medicare Standardized Payment Amount 18425429.23 Drug Suppress Indicator Number of HCPCS Associated With Drug Services 0 Number of Medicare Beneficiaries With Drug Services 0 Number of Drug Services 0 Total Drug Submitted Charge Amount 0 Total Drug Medicare Allowed Amount 0 Total Drug Medicare Payment Amount 0 Total Drug Medicare Standardized Payment Amount 0 Medical Suppress Indicator Number of HCPCS Associated With Medical Services 85 Number of Medicare Beneficiaries With Medical 88121 Number of Medical Services 362298 Total Medical Submitted Charge Amount 81037226.13 Total Medical Medicare Allowed Amount 23098970.26 Total Medical Medicare Payment Amount 18842466.16 Total Medical Medicare Standardized Payment Amount 18425429.23 Average Age of Beneficiaries 73 Number of Beneficiaries Age LNumber of Beneficiaries Age 65 to 74 48174 Number of Beneficiaries Age 75 to 84 27659 Number of Beneficiaries Age GreaNumber of Female Beneficiaries 44917 Number of Male Beneficiaries 43204 Number of Non-Hispanic White Beneficiaries 75763 Number of Black or African American Beneficiaries 3062 Number of Asian Pacific Islander Beneficiaries 1944 Number of Hispanic Beneficiaries 4119 Number of American Indian/Alaska Native Beneficiaries 278 Number of Beneficiaries With Race Not Elsewhere Classified 2955 Number of Beneficiaries With Medicare & Medicaid Entitlement 7445 Number of Beneficiaries With Medicare Only Entitlement 80676 Percent (%) of Beneficiaries Identified With Atrial Fibrillation 0.09 Percent (%) of Beneficiaries Identified With Alzheimer's Disease or Dementia 0.07 Percent (%) of Beneficiaries Identified With Asthma 0.06 Percent (%) of Beneficiaries Identified With Cancer 0.14 Percent (%) of Beneficiaries Identified With Heart Failure 0.11 Percent (%) of Beneficiaries Identified With Chronic Kidney Disease 0.26 Percent (%) of Beneficiaries Identified With Chronic Obstructive Pulmonary Disease 0.1 Percent (%) of Beneficiaries Identified With Depression 0.18 Percent (%) of Beneficiaries Identified With Diabetes 0.25 Percent (%) of Beneficiaries Identified With Hyperlipidemia 0.61 Percent (%) of Beneficiaries Identified With Hypertension 0.63 Percent (%) of Beneficiaries Identified With Ischemic Heart Disease 0.3 Percent (%) of Beneficiaries Identified With Osteoporosis 0.09 Percent (%) of Beneficiaries Identified With Rheumatoid Arthritis / Osteoarthritis 0.4 Percent (%) of Beneficiaries Identified With Schizophrenia / Other Psychotic Disorders 0.01 Percent (%) of Beneficiaries Identified With Stroke 0.03 Average HCC Risk Score of Beneficiaries 0.For El Monte-based clinical diagnostic testing company Fulgent Genetics Inc., the Covid testing surge that catapulted the company from $32 million in annual revenue to the doorstep of $1 billion in just two years has now all but ended. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |